Particle-mediated delivery of cytokines for immunotherapy.
暂无分享,去创建一个
[1] D. Fan,et al. Cytotoxic Potential of Liposomes Containing Tumor Necrosis Factor-α Against Sensitive and Resistant Target Cells , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[2] Y. Barenholz,et al. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. , 1999, Vaccine.
[3] J. Imanishi,et al. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. , 1992, Vaccine.
[4] E. Saravolac,et al. Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ☆ , 1996, Antiviral Research.
[5] P. Wyde,et al. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. , 1990, Vaccine.
[6] I. Fidler,et al. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. , 1980, Cancer research.
[7] D. A. Eppstein,et al. Partial dissociation of antiviral and antimitogenic activities of murine interferon after its incorporation into liposomes. , 1983, Journal of Interferon Research.
[8] B. Narasimhan,et al. Design of a Protective Single-Dose Intranasal Nanoparticle-Based Vaccine Platform for Respiratory Infectious Diseases , 2011, PloS one.
[9] I. Fidler,et al. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. , 1985, Journal of immunology.
[10] I. Fidler,et al. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. , 1983, The Journal of clinical investigation.
[11] D. Liggitt,et al. Immunomodulatory and Toxic Effects of Free and Liposome-encapsulated Tumor Necrosis Factor α in Rats , 1990 .
[12] D. Crommelin,et al. Conformational stability of human interferon-gamma on association with and dissociation from liposomes. , 2000, Journal of pharmaceutical sciences.
[13] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[14] J. Bystryn,et al. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice , 2006, Cancer Immunology, Immunotherapy.
[15] Y. Barenholz,et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. , 2003, Vaccine.
[16] E. Butcher,et al. The germinal center response is impaired in the absence of T cell‐expressed CXCR5 , 2007, European journal of immunology.
[17] B. Amsden,et al. Interferon‐γ therapy: Evaluation of routes of administration and delivery systems , 2002 .
[18] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[19] D. Pettit,et al. Biodegradable polymers for protein and peptide drug delivery. , 1995, Bioconjugate chemistry.
[20] M. C. Popescu,et al. A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. , 2007, Blood.
[21] D. Longo,et al. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. , 1991, Cancer research.
[22] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[23] M. Baca-Estrada,et al. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[24] P. Morrissey,et al. Characterization of Poly(glycolide-co-D,L-lactide)/Poly(D,L-lactide) Microspheres for Controlled Release of GM-CSF , 1997, Pharmaceutical Research.
[25] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[26] S. Crotty,et al. Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.
[27] P. Ellis,et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial , 2011, Journal of Cancer Research and Clinical Oncology.
[28] Gregory Gregoriadis,et al. Liposomes As Immunological Adjuvants and Vaccine Carriers , 1996 .
[29] E. Jaffee,et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.
[30] Peter Scheurich,et al. Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. , 2005, Bioconjugate chemistry.
[31] J. Cleland,et al. Stable Formulations of Recombinant Human Growth Hormone and Interferon-γ for Microencapsulation in Biodegradable Mircospheres , 1996, Pharmaceutical Research.
[32] R. Debs,et al. Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies. , 1989, Journal of immunology.
[33] C. A. Santos,et al. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model , 1998, Cancer Immunology, Immunotherapy.
[34] B. Car,et al. The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.
[35] I. Fidler,et al. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. , 1985, Journal of immunology.
[36] E. Fikrig,et al. TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis , 2010, The Journal of Immunology.
[37] Soong Ho Um,et al. Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.
[38] G Gregoriadis,et al. The carrier potential of liposomes in biology and medicine (second of two parts). , 1976, The New England journal of medicine.
[39] I. Fidler,et al. Liposomal delivery of biological response modifiers to macrophages , 1991, Biotherapy.
[40] I. Bakker-Woudenberg,et al. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria Monocytogenes , 1993, Biotherapy.
[41] Y. Perrie,et al. Liposome-based cationic adjuvant formulations (CAF): Past, present, and future , 2009, Journal of liposome research.
[42] R. K. Rana,et al. Controlled Release of Interleukin-2 from Biodegradable Microspheres , 1990, Bio/Technology.
[43] J Cohen,et al. IL-12 Deaths: Explanation and a Puzzle , 1995, Science.
[44] I. Fidler,et al. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. , 1979, Cancer research.
[45] J. Benoit,et al. Development and characterization of interleukin-18-loaded biodegradable microspheres. , 2006, International journal of pharmaceutics.
[46] I. Fidler,et al. In situ activation of murine macrophages by liposomes containing lymphokines. , 1980, Cellular immunology.
[47] R. J. Kelleher,et al. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. , 2009, Clinical immunology.
[48] H. Alpár,et al. Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6. , 2002, Vaccine.
[49] J. Oppenheim,et al. Cytokines: Past, Present, and Future , 2001, International journal of hematology.
[50] C. Bucana,et al. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. , 1995, AIDS research and human retroviruses.
[51] M. Sabel,et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.
[52] T. Fahmy,et al. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[53] B. Narasimhan,et al. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. , 2011, Acta biomaterialia.
[54] Wim E. Hennink,et al. Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles , 2000, Pharmaceutical Research.
[55] C. Bucana,et al. Superior antiproliferative effects mediated by interferon-alpha entrapped in liposomes against a newly established human lung cancer cell line. , 1990, Journal of biological response modifiers.
[56] C. Butts,et al. L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.
[57] C. Alving,et al. Liposomes as carriers of antigens and adjuvants. , 1991, Journal of immunological methods.
[58] D. Crommelin,et al. Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines , 2004, Pharmaceutical Research.
[59] F. Dosio,et al. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.
[60] L. Babiuk,et al. Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. , 1997, Vaccine.
[61] M. Tsujimoto,et al. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. , 2000, Cancer letters.
[62] A. Bonetti,et al. Pharmacokinetics of an extended-release human interferon alpha-2b formulation , 2004, Cancer Chemotherapy and Pharmacology.
[63] S. Yuk,et al. Polymeric protein delivery systems , 2007 .
[64] M. Lohmann‐Matthes,et al. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes. , 1991, Journal of interferon research.
[65] I. Fidler,et al. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. , 1980, Journal of immunology.
[66] M. Nishio,et al. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. , 2011, Japanese journal of clinical oncology.
[67] Dennis E Discher,et al. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[68] P. Ellis,et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. , 2010, Clinical lung cancer.
[69] E. Abraham,et al. Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. , 1992, Journal of immunology.
[70] W. Stewart,et al. Binding and capture of human interferon-alpha by reverse evaporation vesicles, multilamellar vesicles, and small unilamellar vesicles. , 1981, Journal of interferon research.
[71] M. D'souza,et al. Sustained-release interleukin-12 microspheres in the treatment of cancer. , 1999, Drug development and industrial pharmacy.
[72] A. Chang,et al. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. , 2007, Surgery.
[73] D. Crommelin,et al. Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] P. Felgner,et al. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[75] R. Ho,et al. Differential Disposition of Soluble and Liposome-Formulated Human Recombinant Interleukin-7: Effects on Blood Lymphocyte Population in Guinea Pigs , 1994, Pharmaceutical Research.
[76] T. Fahmy,et al. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. , 2011, Trends in biotechnology.
[77] A. Duits,et al. Immunoadjuvant activity of a liposomal IL-6 formulation. , 1993, Vaccine.
[78] B. Conway,et al. Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-gamma: effect of dose and formulation. , 1998, Vaccine.
[79] T. Ohno,et al. Controlled release of interleukin-2 for tumour immunotherapy using alginate/chitosan porous microspheres , 1997 .
[80] Jason Park,et al. Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. , 2011, Molecular pharmaceutics.
[81] T. Tadakuma,et al. Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2 , 1991, Biotherapy.
[82] N. S. Postma,et al. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. , 1999, The Journal of pharmacology and experimental therapeutics.
[83] M. C. Popescu,et al. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. , 1998, Journal of immunology.
[84] A. Eggermont,et al. Pegylated liposomal tumor necrosis factor‐α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma‐bearing rats , 2002, International journal of cancer.
[85] K. Griffith,et al. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer , 2010, Breast Cancer Research and Treatment.
[86] I. Bakker-Woudenberg,et al. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. , 1995, The Journal of infectious diseases.
[87] I. Fidler,et al. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. , 1985, Cancer research.
[88] D. Gridley,et al. Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[89] I. Fidler,et al. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. , 1984, Science.
[90] I. Fidler,et al. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. , 1984, Journal of immunology.
[91] M. Alonso,et al. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[92] M. Bar‐eli,et al. Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors. , 1994, Cytokine.
[93] R. Langer,et al. Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.
[94] M. Sabel,et al. Neoadjuvant intratumoral cytokine‐loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti‐tumor immunity , 2006, Journal of surgical oncology.
[95] P. Anderson,et al. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma. , 1994, Cytokine.
[96] J. Cleland,et al. Factors affecting the in vitro release of recombinant human interferon‐γ (rhIFN‐γ) from PLGA microspheres , 1997 .
[97] Y. Barenholz,et al. Delivery of Cytokines by Liposomes. II. Interleukin‐2 Encapsulated in Long‐Circulating Sterically Stabilized Liposomes: Immunomodulatory and Anti‐Tumor Activity in Mice , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[98] Y. Perrie,et al. Liposomal vaccine delivery systems , 2011, Expert opinion on drug delivery.
[99] M. Atkins,et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[100] W. Gillanders,et al. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[101] Wah Chiu,et al. Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.
[102] E. Mathiowitz,et al. Cytokines Delivered by Biodegradable Microspheres Promote Effective Suppression of Human Tumors by Human Peripheral Blood Lymphocytes in the SCID–Winn Model , 2000, Journal of immunotherapy.
[103] M. Lohmann‐Matthes,et al. Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo. , 1989, Journal of interferon research.
[104] Mohamed A. Shaker,et al. Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. , 2009, Journal of pharmaceutical sciences.
[105] Y. Barenholz,et al. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. , 1997, Journal of immunotherapy.
[106] M. C. Popescu,et al. In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. , 2001, Cytokine.
[107] W. Hennink,et al. IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. , 2003, Cytokine.
[108] Y. Barenholz,et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults , 2003, Journal of medical virology.
[109] P. Poindron,et al. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. , 1996, The American journal of physiology.
[110] E. Mathiowitz,et al. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. , 2004, Cancer biotherapy & radiopharmaceuticals.
[111] J. Irache,et al. Gamma Interferon Loaded onto Albumin Nanoparticles: In Vitro and In Vivo Activities against Brucella abortus , 2007, Antimicrobial Agents and Chemotherapy.
[112] F. Falkenberg,et al. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. , 1999, Journal of immunotherapy.
[113] Qiang Zhou,et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6 , 2009, Cell cycle.
[114] W. Stewart,et al. Altered pharmacological properties of liposome-associated human interferon-alpha. , 1982, Journal of virology.
[115] Y. Barenholz,et al. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. , 2000, Journal of immunotherapy.
[116] P. Scott. IL-12: initiation cytokine for cell-mediated immunity. , 1993, Science.
[117] M. Ratain,et al. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. , 1986, Cancer treatment reports.
[118] R. Langer,et al. Microparticulate formulations for the controlled release of interleukin-2. , 2004, Journal of pharmaceutical sciences.
[119] D. Irvine,et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.
[120] R. J. Kelleher,et al. Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-γ, and Eradicate Tumor Cells1 , 2005, The Journal of Immunology.
[121] D. Fan,et al. Antitumor effects of liposomal IL1α and TNFα against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice , 1995, Clinical & Experimental Metastasis.
[122] I. Fidler,et al. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. , 1982, Cancer research.
[123] M. Choti,et al. Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors , 2001, Pharmaceutical Research.
[124] P. Poindron,et al. Preparation and characterization of interferon-γ-containing liposomes , 1995 .
[125] Keunchil Park,et al. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer , 2011, BMC Cancer.
[126] S. North,et al. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer , 2007, Expert opinion on biological therapy.
[127] A. Chang,et al. Intratumoral IL-12 and TNF-α–Loaded Microspheres Lead To Regression of Breast Cancer and Systemic Antitumor Immunity , 2004, Annals of Surgical Oncology.
[128] I. Fidler,et al. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. , 1981, Cancer research.
[129] G. Storm,et al. Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines , 2001 .
[130] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[131] S. Bernstein,et al. Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-γ1 , 2003, The Journal of Immunology.
[132] Y. Bae,et al. Novel approaches in microparticulate PLGA delivery systems encapsulating proteins , 2007 .
[133] Y. Barenholz,et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. , 2001, Vaccine.
[134] E. Voronov,et al. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. , 2000, Cytokine.
[135] E. Chang,et al. Induction of heat shock protein 70 protects intestinal epithelial IEC-18 cells from oxidant and thermal injury. , 1996, The American journal of physiology.
[136] J. Berzofsky,et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function , 2005, The Journal of experimental medicine.
[137] M. C. Popescu,et al. Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen , 2004, Clinical Cancer Research.
[138] I. Fidler. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. , 1980, Science.
[139] P. Anderson,et al. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[140] Sang-Nae Cho,et al. Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination , 2006, Infection and Immunity.
[141] M. C. Popescu,et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. , 2007, Blood.
[142] J. Vansteenkiste,et al. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[143] G. Trinchieri,et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major , 1994 .
[144] D. Crommelin,et al. Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. , 2001, Biochimica et biophysica acta.
[145] G. Storm,et al. Liposomes as cytokine-supplement in tumor cell-based vaccines. , 1999, International journal of pharmaceutics.
[146] A. Eggermont,et al. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats , 1998, International journal of cancer.
[147] M. Sabel,et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.
[148] G. Gregoriadis. The Carrier Potential of Liposomes in Biology and Medicine , 1976 .
[149] M. Sabel,et al. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. , 2001, Surgery.
[150] Liposomes as immunological adjuvants , 1974 .
[151] G. Gregoriadis,et al. Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo. , 1997, Immunology letters.
[152] A. Olivi,et al. Local Immunotherapy with Interleukin-2 Delivered from Biodegradable Polymer Microspheres Combined with Interstitial Chemotherapy: A Novel Treatment for Experimental Malignant Glioma , 2003, Neurosurgery.
[153] P. Anderson,et al. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. , 1990, Cancer research.